Dermatology · Tarrytown, NY
NPI
1902832777
Since 2006
Specialty
Dermatology
Code 207N00000X
Group practices
3
Medicare group memberships
Hospitals
0
Hospital affiliations
155 White Plains Road, Suite 109 East Wing
Tarrytown, NY, 10591
Phone (914) 829-8200
Groups this clinician bills Medicare through
Medicare paid, 2024
$39K
757 services
Medicare patients, 2024
203
Average age 74
Drug cost, 2024
$2.4M
2,601 prescriptions
Company payments, 2025
$8,161
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kristina Campton was code 17003 (destruction skin lesion), 203 times for 40 patients. In total Kristina Campton billed 757 services in 22 codes, and Medicare paid $39K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-01-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 203 | 40 | $5.66 | $1,149 |
| 99214 Office E&M - Established | Office | 82 | 48 | $81.75 | $6,703 |
| 99213 Office E&M - Established | Office | 76 | 60 | $75.53 | $5,741 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 75 | 52 | $14.12 | $1,059 |
| 17000 Destruction Skin Lesion | Office | 73 | 51 | $47.56 | $3,472 |
| 17110 Destruction Skin Lesion | Office | 72 | 57 | $100.61 | $7,244 |
| 99203 Office E&M - New | Office | 47 | 47 | $95.02 | $4,466 |
| 99212 Office E&M - Established | Office | 35 | 32 | $50.32 | $1,761 |
| 11102 Skin Biopsy | Office | 31 | 30 | $69.95 | $2,168 |
| 99202 Office E&M - New | Office | 22 | 22 | $60.15 | $1,323 |
| 99204 Office E&M - New | Office | 12 | 12 | $123.79 | $1,485 |
By year: 2022 $20K for 242 services; 2023 $18K for 242 services; 2024 $39K for 757 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kristina Campton prescribed most often to Medicare patients was Opzelura (Ruxolitinib Phosphate), with 557 prescriptions and refills. In total Kristina Campton wrote 2,601 Medicare prescriptions that cost $2.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Opzelura Ruxolitinib Phosphate | 557 | 557 | 81 | $1.1M |
| Clobetasol Propionate Generic | 318 | 319 | 94 | $20K |
| Triamcinolone Acetonide Generic | 271 | 308 | 111 | $5,205 |
| Finasteride Generic | 227 | 484 | 65 | $2,070 |
| Ketoconazole Generic | 152 | 158 | 53 | $2,547 |
| Minoxidil Generic | 113 | 179 | 30 | $1,200 |
| Rinvoq Upadacitinib | 94 | 94 | 13 | $626K |
| Spironolactone Generic | 70 | 84 | 15 | $695 |
| Tretinoin Generic | 61 | 64 | 26 | $4,755 |
| Betamethasone Dipropionate Generic | 56 | 58 | 21 | $2,435 |
| Gabapentin Generic | 54 | 67 | Under 11 | $619 |
| Clindamycin Phosphate Generic | 51 | 56 | Under 11 | $1,821 |
| Halobetasol Propionate Generic | 48 | 50 | 14 | $3,623 |
| Minocycline Hcl Generic | 41 | 41 | Under 11 | $1,131 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 35 | 35 | 11 | $2,341 |
Brand drugs: 821 claims; generic drugs: 1,780 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kristina Campton $8,161 ($8,161 in general payments such as food, travel and fees) from 19 companies. The largest payer was Incyte Corporation with $2,914.
| Company | Payments | Amount |
|---|---|---|
| Incyte Corporation INCY | 66 | $2,914 |
| Abbvie Inc. ABBV | 25 | $2,292 |
| UCB, Inc. UCB.BR | 40 | $625 |
| Pfizer Inc. PFE | 32 | $461 |
| Janssen Biotech, Inc. JNJ | 19 | $320 |
| Arcutis Biotherapeutics, Inc. ARQT | 34 | $284 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 17 | $206 |
| Botanix SB Inc | 11 | $168 |
| Galderma Laboratories, L.P. GALD.SW | 16 | $136 |
| Genzyme Corporation SNY | 5 | $130 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.